Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans
NCT05145309Phase 2Not yet recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Nov 2026
- Primary completion
- Dec 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of potassium citrate + magnesium citrate in hypertension (HTN) (2 arms), sponsored by UT Southwestern Medical Center. Primary endpoint: 24-hour systolic blood pressure at 4 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
potassium citrate + magnesium citrate
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05145309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05145309.